Login name: Password:

ENKAM Pharmaceuticals A/S is a Copenhagen-based biotechnology company focused on the R&D of peptides for the treatment of CNS disorders and cancer and most recently for stem cell applications. ENKAM uses basic structural proteomics tools (NMR titration, X-ray crystallography and surface plasmon resonance (SPR) analyses and peptide synthesis) and bio-informatics to determine binding sites between the receptors and their ligands, discover bioactive peptides specifically binding to these targets and optimize their profile. Over 50 peptide families have been identified and patents covering them have been filed. The lead compound FGL has recently successfully completed a Phase 1 Clinical Trial, and clinical trials in patients with Alzheimer’s disease are expected to start in 2009-2010. ENKAM is a leading member of the FP6 consortium PROMEMORIA and of the FP7 consortium.
MEMSTICK. All R&D “wet”activities of the company are run via collaborations with academic and industrial partners and CRO. ENKAM will collaborate for peptide production and analysis tasks and training with peptides&elephants GmbH, Nuthetal, Germany.
Web page: http://www.enkam.com